Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation - Results from a randomized controlled clinical trial

被引:181
作者
Hendrikx, M
Hensen, K
Clijsters, C
Jongen, H
Koninckx, R
Bijnens, E
Ingels, M
Jacobs, A
Geukens, R
Dendale, P
Vijgen, J
Dilling, D
Steels, P
Mees, U
Rummens, JL
机构
[1] Virga Jessehosp, Dept Cardiothorac Surg, B-3500 Hasselt, Belgium
[2] Virga Jessehosp, MRI Unit, Dept Radiol, B-3500 Hasselt, Belgium
[3] Virga Jessehosp, Dept Cardiol, B-3500 Hasselt, Belgium
[4] Hasselt Univ, Biomed Inst, Fac Med, Diepenbeek, Belgium
关键词
clinical trial; myocardial infarction; stem cells;
D O I
10.1161/CIRCULATIONAHA.105.000505
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background-Recent trials have shown that intracoronary infusion of bone marrow cells (BMCs) improves functional recovery after acute myocardial infarction. However, whether this treatment is effective in heart failure as a consequence of remodeling after organized infarcts remains unclear. In this randomized trial, we assessed the hypothesis that direct intramyocardial injection of autologous mononuclear bone marrow cells during coronary artery bypass graft (CABG) could improve global and regional left ventricular ejection fraction (LVEF) at 4-month follow-up. Methods and Results-Twenty patients (age 64.8 +/- 8.7; 17 male, 3 female) with a postinfarction nonviable scar, as assessed by thallium (Tl) scintigraphy and cardiac magnetic resonance imaging (MRI), scheduled for elective CABG, were included. They were randomized to a control group (n=10, CABG only) or a BMC group (CABG and injection of 60.10(6)+/- 31.10(6) BMC). Primary end points were global LVEF change and wall thickening changes in the infarct area from baseline to 4-month follow-up, as measured by MRI. Changes in metabolic activity were measured by Tl scintigraphy and expressed as a score with a range from 0 to 4, corresponding to percent of maximal myocardial Tl uptake (4 indicates < 50%, nonviable scar; 3, 50% to 60%; 2, 60% to 70%; 1, 70% to 80%; 0 > 80%). Global LVEF at baseline was 39.5 +/- 5.5% in controls and 42.9 +/- 10.3% in the BMC group (P=0.38). At 4 months, LVEF had increased to 43.1 +/- 10.9% in the control group and to 48.9 +/- 9.5% in the BMC group (P=0.23). Systolic thickening had improved from -0.6 +/- 1.3 mm at baseline to 1.8 +/- 2.6 mm at 4 months in the cell-implanted scars, whereas nontreated scars remained largely akinetic (-0.5 +/- 2.0 mm at baseline compared with 0.4 +/- 1.7 mm at 4 months, P=0.007 control versus BMC-treated group at 4 months). Defect score decreased from 4 to 3.3 +/- 0.9 in the BMC group and to 3.7 +/- 0.4 in the control group (P=0.18). Conclusions-At 4 months, there was no significant difference in global LVEF between both groups, but a recovery of regional contractile function in previously nonviable scar was observed in the BMC group.
引用
收藏
页码:I101 / I107
页数:7
相关论文
共 24 条
[1]
Endothelial progenitor cells for postnatal vasculogenesis [J].
Asahara, T ;
Kawamoto, A .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2004, 287 (03) :C572-C579
[2]
Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction -: (TOPCARE-AMI) [J].
Assmus, B ;
Schächinger, V ;
Teupe, C ;
Britten, M ;
Lehmann, R ;
Döbert, N ;
Grünwald, F ;
Aicher, A ;
Urbich, C ;
Martin, H ;
Hoelzer, D ;
Dimmeler, S ;
Zeiher, AM .
CIRCULATION, 2002, 106 (24) :3009-3017
[3]
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium [J].
Balsam, LB ;
Wagers, AJ ;
Christensen, JL ;
Kofidis, T ;
Weissman, IL ;
Robbins, RC .
NATURE, 2004, 428 (6983) :668-673
[4]
Partial restoration of myocardial function and perfusion by cell therapy following myocardial infarction [J].
Bick-Forrester, J ;
Lee, MS ;
Makkar, RR ;
Forrester, JS .
CURRENT OPINION IN CARDIOLOGY, 2004, 19 (06) :631-637
[5]
Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium - Short- and long-term effects [J].
Dai, WD ;
Hale, SL ;
Martin, BJ ;
Kuang, JQ ;
Dow, JS ;
Wold, LE ;
Kloner, RA .
CIRCULATION, 2005, 112 (02) :214-223
[6]
Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction [J].
Fernández-Avilés, F ;
San Román, JA ;
García- Frade, J ;
Fernández, ME ;
Peñarrubia, MJ ;
de la Fuente, L ;
Gómez-Bueno, M ;
Cantalapiedra, A ;
Fernández, J ;
Gutierrez, O ;
Sánchez, PL ;
Hernández, C ;
Sanz, R ;
García-Sancho, J ;
Sánchez, A .
CIRCULATION RESEARCH, 2004, 95 (07) :742-748
[7]
Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans [J].
Galiñanes, M ;
Loubani, M ;
Davies, J ;
Chin, D ;
Pasi, J ;
Bell, PR .
CELL TRANSPLANTATION, 2004, 13 (01) :7-13
[8]
The predictive value of 201Tl rest-redistribution and 18F-fluorodeoxyglucose SPECT for wall motion recovery after recent reperfused myocardial infarction [J].
González, P ;
Massardo, T ;
Coll, C ;
Humeres, P ;
Sierralta, P ;
Jofré, MJ ;
Yovanovich, J ;
Aramburu, I ;
Brugère, S ;
Chamorro, H .
ANNALS OF NUCLEAR MEDICINE, 2004, 18 (02) :97-103
[9]
Monitoring of bone marrow cell homing into the infarcted human myocardium [J].
Hofmann, M ;
Wollert, KC ;
Meyer, GP ;
Menke, A ;
Arseniev, L ;
Hertenstein, B ;
Ganser, A ;
Knapp, WH ;
Drexler, H .
CIRCULATION, 2005, 111 (17) :2198-2202
[10]
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial [J].
Janssens, S ;
Dubois, C ;
Bogaert, J ;
Theunissen, K ;
Deroose, C ;
Desmet, W ;
Kolantzi, M ;
Herbots, L ;
Sinnaeve, P ;
Dens, J ;
Maertens, J ;
Rademakers, F ;
Dymarkowski, S ;
Gheysens, O ;
Van Cleemput, J ;
Bormans, G ;
Nuyts, J ;
Belmans, A ;
Mortelmans, L ;
Boogaerts, M ;
Van de Werf, F .
LANCET, 2006, 367 (9505) :113-121